- Home
- PSHG vs CYTH Comparison
PSHG vs CYTH Comparison
Compare PSHG & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- CYTH
- Stock Information
- Founded
- PSHG 2010
- CYTH 1990
- Country
- PSHG Greece
- CYTH United States
- Employees
- PSHG N/A
- CYTH N/A
- Industry
- PSHG Marine Transportation
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- CYTH Health Care
- Exchange
- PSHG Nasdaq
- CYTH Nasdaq
- Market Cap
- PSHG 20.3M
- CYTH 20.4M
- IPO Year
- PSHG N/A
- CYTH N/A
- Fundamental
- Price
- PSHG $1.87
- CYTH $0.66
- Analyst Decision
- PSHG Strong Buy
- CYTH Buy
- Analyst Count
- PSHG 1
- CYTH 3
- Target Price
- PSHG $6.50
- CYTH $0.95
- AVG Volume (30 Days)
- PSHG 79.5K
- CYTH 41.7K
- Earning Date
- PSHG 11-07-2024
- CYTH 11-14-2024
- Dividend Yield
- PSHG N/A
- CYTH N/A
- EPS Growth
- PSHG N/A
- CYTH N/A
- EPS
- PSHG 1.51
- CYTH N/A
- Revenue
- PSHG $89,608,000.00
- CYTH $870,725.00
- Revenue This Year
- PSHG N/A
- CYTH N/A
- Revenue Next Year
- PSHG $1.85
- CYTH $24.49
- P/E Ratio
- PSHG $1.23
- CYTH N/A
- Revenue Growth
- PSHG N/A
- CYTH N/A
- 52 Week Low
- PSHG $1.61
- CYTH $0.57
- 52 Week High
- PSHG $2.58
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- PSHG 52.75
- CYTH 47.76
- Support Level
- PSHG $1.82
- CYTH $0.60
- Resistance Level
- PSHG $1.95
- CYTH $0.66
- Average True Range (ATR)
- PSHG 0.11
- CYTH 0.05
- MACD
- PSHG 0.01
- CYTH 0.00
- Stochastic Oscillator
- PSHG 64.29
- CYTH 46.67
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.